<SEC-DOCUMENT>0001213900-22-055199.txt : 20220912
<SEC-HEADER>0001213900-22-055199.hdr.sgml : 20220912
<ACCEPTANCE-DATETIME>20220912080208
ACCESSION NUMBER:		0001213900-22-055199
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220912
FILED AS OF DATE:		20220912
DATE AS OF CHANGE:		20220912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		221237408

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea165439-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
6-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of: September 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-36578</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><U>ENLIVEX
THERAPEUTICS LTD.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>14
Einstein Street, Nes Ziona, Israel 7403618</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2022, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the &ldquo;Company&rdquo;),
issued a press release announcing new preclinical data in a murine mesothelioma model showing a substantial and statistically significant
survival benefit when Allocetra&trade; is combined with the chemotherapeutic agent, cisplatin. A copy of such press release is furnished
as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="ea165439ex99-1_enlivex.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Press Release issued by Enlivex Therapeutics Ltd. on September 12, 2022.</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">Enlivex Therapeutics Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
September 12, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea165439ex99-1_enlivex.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="image_001.jpg" ALT="Logo, company name&#10;&#10;Description automatically generated" STYLE="height: 126px; width: 201px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Enlivex Announces New Preclinical Data in Murine
Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO
Congress 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Currently used cisplatin-based combination
treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers </I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Combining cisplatin with Allocetra&trade;
led to a substantial and statistically significant survival benefit in a murine mesothelioma model, with a survival rate of 55% observed
in the combination therapy group versus rates of 0% in untreated and cisplatin monotherapy groups, and 14.2% in the Allocetra&trade; monotherapy
group</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Data highlight Allocetra&rsquo;s&trade; broadly
applicable immunotherapeutic effects and support an ongoing Phase I/II trial evaluating Allocetra&trade; combined with chemotherapy in
patients with peritoneal metastases arising from solid cancer</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Nes-Ziona, Israel, September 12, 2022 <FONT STYLE="color: black">(GLOBE
NEWSWIRE) </FONT></B>&ndash; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the &ldquo;Company&rdquo;), a clinical-stage macrophage reprogramming
immunotherapy company, today announced new preclinical data in a murine mesothelioma model showing a substantial and statistically significant
survival benefit when Allocetra&trade; is combined with the chemotherapeutic agent, cisplatin. The data are featured in a poster being
presented at the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place both virtually and in-person at the
Paris Expo Porte de Versailles in Paris, France from September 9, 2022 through September 13, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Data featured in the ESMO poster are from preclinical
studies in mice implanted with AB12 mesothelioma cells. Following implantation, mice were given vehicle (untreated group), intravenous
(IV) cisplatin monotherapy, Allocetra&trade; monotherapy administered intraperitoneally (IP), or IV cisplatin in combination with IP Allocetra&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On day-57 post-implantation, the survival rate in
the untreated group was 0%, and the mean survival duration was 31.7 &plusmn; 2.6 days. These were similar to the survival rate of 0% and
slightly superior mean survival duration of 36.2 &plusmn; 5.0 days in the cisplatin monotherapy group. The survival rate and mean duration
in the Allocetra&trade; monotherapy group were 14.2%, and 40.4 &plusmn; 10.9 days, respectively. When Allocetra&trade; was combined with
cisplatin, a synergistic anti-cancer effect was observed, as the survival rate and mean duration in the combination therapy group were
55% and 49.3 &plusmn; 10.6 days, respectively. Notably, the increase in survival duration observed in the combination therapy group was
statistically significant compared to the untreated group (p=0.0033, log rank), cisplatin monotherapy group ( p=0.0035, log rank), and
Allocetra&trade; monotherapy (p=0.0413, log rank) group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also featured in the ESMO poster are preclinical mesothelioma
data showing a substantial survival benefit when Allocetra&trade; is combined with an anti-PD1 checkpoint inhibitor, and previously presented
preclinical data in mesothelioma showing a substantial survival benefit when Allocetra&trade; is combined with a commercially approved
anti-CTLA4 checkpoint inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Our latest data add to an extensive body of
preclinical evidence demonstrating Allocetra&rsquo;s<I>&trade;</I> potential to address unmet needs in a variety of difficult-to-treat
solid cancers,&rdquo; said Prof. Dror Mevorach, M.D., Chief Scientific Officer of Enlivex and co-author of the poster. &ldquo;The disproportionate
presence of pro-tumor macrophages in tumor microenvironments severely limits the efficacy of many drug classes, including both immuno-
and chemotherapies. With Allocetra&trade;, we believe we can reprogram resident macrophages back to their homeostatic state, thereby enhancing
the efficacy of complementary anti-cancer agents and avoiding the accumulation of pro-tumor macrophages. The data being presented at ESMO
provide additional support for this hypothesis, as they highlight the potential benefits of combining Allocetra&trade; with cisplatin
or immune checkpoint inhibitors such as anti-PD1 or anti-CTLA4. We look forward to discussing our findings with the medical community
at this year&rsquo;s congress.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Oren Hershkovitz, Ph.D., Chief Executive Officer of
Enlivex, commented, &ldquo;We are very pleased with the results of these preclinical studies, which support our ongoing Phase I/II trial
evaluating Allocetra&trade; plus chemotherapy in patients with peritoneal metastases. This trial has been carefully designed to clinically
demonstrate Allocetra&rsquo;s<I>&trade;</I> novel mechanism of action and further our understanding of its safety profile and anti-cancer
activity. Successfully achieving these goals would represent a key milestone, as it would bring us substantially closer to providing cancer
patients with a novel and highly scalable next-generation cell therapy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Mesothelioma, Treatment Landscape, and Macrophage-Solid
Tumor Dynamics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mesothelioma is one of the deadliest solid cancers,
with the few available treatment options having limited efficacy. These include checkpoint inhibitors targeting CTLA4 and PD1, as well
as cisplatin-based combinations. People most at risk for mesothelioma generally have had long-term exposure to asbestos (e.g., construction
workers, pipe fitters, and shipyard workers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In mesothelioma and other solid cancers, the efficacy
of many anti-cancer agents is limited by tumor mechanisms that facilitate the recruitment of macrophages that become &quot;pro-tumor&quot;
tumor associated macrophages (TAMs) rather than &quot;anti-tumor&quot; macrophages. The TAMs typically form a physical layer on top of
the solid tumor and promote tumor growth and metastasis, thereby contributing to poor clinical outcomes and response to therapy. Allocetra&trade;
is a cell therapy in development that targets these TAMs. Allocetra&rsquo;s <I>&trade;</I> proposed mechanism of action is to change the
balance of macrophage populations so that they skew towards anti-tumor macrophages and away from pro-tumor macrophages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ESMO poster (#479P) is titled, &ldquo;Synergistic
anti-tumor effect of Allocetra-OTS in combination with immune checkpoint inhibitors (ICI)/chemotherapy/CAR-T, through in-vivo reprogramming
of macrophages.&rdquo; It is currently available for viewing on ESMO&rsquo;s virtual platform and will also be presented by Prof. Mevorach,
during Poster Session 13 of the ESMO Congress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ABOUT ESMO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ESMO is a leading professional organization for medical
oncology. Its core missions are to: (1) improve the quality of cancer care, from prevention and diagnosis all the way to palliative care
and patient follow-up; (2) educate &ndash; doctors, cancer patients and the general public &ndash; on the best practices and latest advances
in oncology; and (3) promote equal access to optimal cancer care for all patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ABOUT ALLOCETRA&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Allocetra&trade; is being developed as a universal,
off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and
many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity
of the respective diseases. By restoring macrophage homeostasis, Allocetra&trade; has the potential to provide a novel immunotherapeutic
mechanism of action for life-threatening clinical indications that are defined as &quot;unmet medical needs&quot;, as a stand-alone therapy
or in combination with leading therapeutic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>ABOUT ENLIVEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; background-color: white">Enlivex is a clinical
stage macrophage reprogramming immunotherapy company developing Allocetra&trade;, a universal, off-the-shelf cell therapy designed to
reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for
immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; background-color: white"><I>Safe Harbor Statement:&nbsp;
This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo;
&ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the potential
to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results
of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs.
All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.&nbsp; Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect&nbsp;Enlivex&rsquo;s&nbsp;business
and prospects, including the risks that&nbsp;Enlivex&nbsp;may not succeed in generating any revenues or developing any commercial products;
that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would
support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may
not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those
set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from
the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more
developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product line could also be affected
by&nbsp;a number of&nbsp;other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for
data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and
the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp; In addition to the risk factors
described above, investors should consider the economic, competitive, governmental,&nbsp;technological&nbsp;and other factors discussed
in&nbsp;Enlivex&rsquo;s&nbsp;filings with the Securities and Exchange Commission, including in the Company&rsquo;s most recent Annual
Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except
as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: white"><B>ENLIVEX CONTACT</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
Shachar Shlosberger, CFO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
Enlivex Therapeutics, Ltd.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Eric Ribner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">eric@lifesciadvisors.com</P>

<P STYLE="color: #666666; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3in">&nbsp;</P>
<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "= /L# 2(  A$! Q$!_\0
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MY&&YF7C_ &4&,_G7G5<F$7,G5>[?X&-%7O-]0HHHKL-@HHHH **** "BBB@
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M 'I5.BBNM))61NE9604444P"BBB@ HHHH **** "BBB@ HHHH 4]3]:2BB@
MHHHH **** "BBM[PKX0O_%]U<0:?);QM;QB1S,Q48SCL#0%[&#17??\ "GM9
M_P"@EH__ ($G_"L_7?AOJ?A_2)M1N;W398H=N4AG+.<D#@8]Z!<R.1HK4/AZ
M^_X1A=>55:Q-P;=B#\R-CJ1Z'-9= PHK8U?PQ>Z+I&EZE<O"T&IQF2$(Q+
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M (K?X;66O1C?J>C_ .C7N.K1]F_D?Q:N/\5^)+CQ7K\^IW*^7OPL<0.1&@Z
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MLA=0VT[EYP?K6C8O&MG8;E9VNGD,L:0*WG<XP2>G'ITZT V84EN\4$,KXV3
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:X[]*RJ*06"BBBF 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
